Report

It is anticipated that extreme weather events due to climate change will increase the prevalence of a number of acute and chronic diseases. As a result, the demand for drugs to prevent or treat those conditions is likely to increase.

The cost of bringing a medical product to the U.S. market has been increasing and clinical trials constitute a large portion of these costs. In drug development, the clinical phase lasts an average of around 95 months compared to 31 months for the non-clinical phase and accounts for 69 percent of overall R&D costs (DiMasi, et al., 2016).

This report highlights key programs, activities, and policies of HHS’ strategic approach to addressing social determinants of health, including early accomplishments to date and stories of the on-the-ground impact that these initiatives are making in people’s lives. These and other actions being taken by HHS, and across the federal government, as well as cross-sector initiatives at the com

This brief summarizes an expert convening focused on the child support program’s current ability and future potential to help address child poverty.Key Findings

The Office of the Assistant Secretary for Planning and Evaluation (ASPE) released a report summarizing lessons learned from using communities of practice (CoPs) to support state, Tribal, local, and territorial (STLT) public health agencies during the COVID-19 pandemic.

The Office of the Assistant Secretary for Planning and Evaluation (ASPE) and the Office of the Assistant Secretary for Health (OASH), in partnership with Mathematica, are conducting a comprehensive study to identify promising practices aimed at reducing disparities in COVID-19 vaccination and testing, and policy options to promote equitable, routine vaccination.

To help the federal government and STLT jurisdictions better prepare for emergencies, there is a need to understand how prepared different jurisdictions are for various emergencies. However, assessing whether a jurisdiction is prepared for different emergencies is inherently complex and there is a lack of consensus among practitioners and scholars on how to approach preparedness measurement.

The evolution of pathogens to resist the drugs used to treat infections is an ongoing threat to public health, animal health, food production, and national security. Globally, a recent analysis estimated that 1.2 million deaths were caused by antibiotic-resistant (AR) bacteria in 2019, making this threat a leading cause of death for people of all ages worldwide.

A 2020 study examined the feasibility of using substance use disorder (SUD) patient intake assessment data as source of information for treatment planning.